| Dendritic cells and cancer: from biology to therapeutic intervention B Wylie, C Macri, JD Mintern, J Waithman Cancers 11 (4), 521, 2019 | 129 | 2019 |
| Resident CD8+ and migratory CD103+ dendritic cells control CD8 T cell immunity during acute influenza infection J Waithman, D Zanker, K Xiao, S Oveissi, B Wylie, R Ng, L Tögel, W Chen PLoS One 8 (6), e66136, 2013 | 78 | 2013 |
| Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103− and XCR1+CD103+ dendritic cells B Wylie, E Seppanen, K Xiao, R Zemek, D Zanker, S Prato, B Foley, ... Oncoimmunology 4 (8), e1019198, 2015 | 37 | 2015 |
| Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation AM McDonnell, AJ Currie, M Brown, K Kania, B Wylie, A Cleaver, R Lake, ... Oncoimmunology 1 (6), 840-846, 2012 | 33 | 2012 |
| The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40 A Khong, AL Cleaver, M Fahmi Alatas, BC Wylie, T Connor, SA Fisher, ... BMC cancer 14, 1-9, 2014 | 28 | 2014 |
| Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens B Wylie, J Chee, CA Forbes, M Booth, SR Stone, A Buzzai, A Abad, ... Oncoimmunology, 2019 | 20 | 2019 |
| Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance AL Cleaver, K Bhamidipaty, B Wylie, T Connor, C Robinson, ... Carcinogenesis 35 (2), 407-414, 2014 | 19 | 2014 |
| Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice RM Zemek, WL Chin, VS Fear, B Wylie, TH Casey, C Forbes, CM Tilsed, ... Nature Communications 13 (1), 4895, 2022 | 17 | 2022 |
| CD8+XCR1neg Dendritic Cells Express High Levels of Toll-Like Receptor 5 and a Unique Complement of Endocytic Receptors B Wylie, J Read, AC Buzzai, T Wagner, N Troy, G Syn, SR Stone, B Foley, ... Frontiers in Immunology 9, 2990, 2019 | 13 | 2019 |
| IFNβ is a potent adjuvant for cancer vaccination strategies KM Audsley, T Wagner, C Ta, HV Newnes, AC Buzzai, SA Barnes, ... Frontiers in Immunology 12, 735133, 2021 | 12 | 2021 |
| Neoadjuvant anti-tumor vaccination prior to surgery enhances survival SA Fisher, A Cleaver, DD Lakhiani, A Khong, T Connor, B Wylie, ... Journal of Translational Medicine 12, 1-9, 2014 | 12 | 2014 |
| Impaired T cell proliferation by ex vivo BET-inhibition impedes adoptive immunotherapy in a murine melanoma model J Chee, C Wilson, A Buzzai, B Wylie, CA Forbes, M Booth, N Principe, ... Epigenetics 15 (1-2), 134-144, 2020 | 11 | 2020 |
| Targeting cross-presentation as a route to improve the efficiency of peptide-based cancer vaccines B Wylie, F Ong, H Belhoul-Fakir, K Priebatsch, H Bogdawa, A Stirnweiss, ... Cancers 13 (24), 6189, 2021 | 8 | 2021 |
| Diverse Anti-Tumor Immune Potential Driven by Individual IFNα Subtypes AC Buzzai, T Wagner, KM Audsley, HV Newnes, LW Barrett, S Barnes, ... Frontiers in Immunology 11, 519512, 2020 | 7 | 2020 |
| Dendritic cells and cancer: from biology to therapeutic intervention. Cancers (Basel) 11 (4) B Wylie, C Macri, JD Mintern, J Waithman | 6 | 2019 |
| Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B‐and T‐cell acute lymphoblastic leukaemia B Foley, C Ta, S Barnes, E de Jong, M Nguyen, LC Cheung, A Buzzai, ... Clinical & Translational Immunology 9 (7), e1151, 2020 | 5 | 2020 |
| A surgically optimized intraoperative poly (I: C)-releasing hydrogel prevents cancer recurrence FX Rwandamuriye, CW Evans, B Wylie, M Norret, B Vitali, D Ho, ... Cell Reports Medicine 4 (7), 2023 | 3 | 2023 |
| Protocol for delivery of intraoperative immunotherapy to mice by surgical debulking of subcutaneous tumors FX Rwandamuriye, B Vitali, J Schreurs, T Wang, E Barrick, KS Iyer, ... STAR protocols 5 (2), 102948, 2024 | | 2024 |
| 1226 Surgery is a window of opportunity: biomaterial-assisted delivery of immunotherapy reduces local recurrence of soft tissue sarcoma BC Wylie, F Rwandamuriye, C Evans, M Norrett, RM Zemek, S Iyer, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Temporally restricted activation of IFNβ signaling determines response to immune checkpoint therapy R Zemek, WL Chin, V Fear, B Wylie, T Casey, C Forbes, C Tilsed, L Boon, ... | | 2021 |
